Page 109 - 2019_07 resto del Mondo-web

Plasmacytoid dendritic cells in AML
mal residual disease during complete remis- sion by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104(10):3078-3085.
13. Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic char- acterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood. 2010;116(13):2295-2303.
14. San Miguel JF, Martinez A, Macedo A, et al. Immunophenotyping investigation of mini- mal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997;90(6):2465-2470.
15. Buccisano F, Maurillo L, Gattei V, et al. The kinetics of reduction of minimal residual dis- ease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia. 2006;20(10):1783- 1789.
16. Al-Mawali A, Gillis D, Hissaria P, Lewis I. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol. 2008;129(6):934-945.
17. van der Velden VHJ, van der Sluijs-Geling A, Gibson BES, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia. 2010;24(9):1599-1606.
18. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal resid- ual disease, as detected by multiparametric flow cytometry, on outcome of myeloabla- tive hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190-1197.
19. Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoi- etic cell transplantation for AML in first and second complete remission. Blood. 2013;122(10):1813-1821.
20. Araki D, Wood BL, Othus M, et al. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission? J Clin Oncol. 2016;34(4):329-336.
21. Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloabla- tive or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29(1):137-1344.
22. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
23. Freeman SD, Hills RK, Virgo P, et al. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations. J Clin Oncol. 2018;36(15):1486- 1497.
Langebrake C, Creutzig U, Dworzak M, et
al. Residual disease monitoring in childhood
acute myeloid leukemia by multiparameter
flow cytometry: the MRD-AML-BFM Study
Group. J Clin Oncol. 2006;24(22):3686-3692.
Baer MR, Stewart CC, Dodge RK, et al. High
frequency of immunophenotype changes in
acute myeloid leukemia at relapse: implica-
tions for residual disease detection (Cancer
and Leukemia Group B Study 8361). Blood. 2001;97(11):3574-3580. 985.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
Hematol. 2010;85(11):893.
38. Song HL, Huang WY, Chen YP, Chang KC.
Wood BL, Arroz M, Barnett D, et al. 2006 Bethesda International Consensus recom- mendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom. 2007;72 Suppl 1:S14-22. Kalina T, Flores-Montero J, van der Velden VH, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010.
van Dongen JJ, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908-1975.
40. Cheng DT, Cheng J, Mitchell TN, et al. Detection of mutations in myeloid malig- nancies through paired-sample analysis of microdroplet-PCR deep sequencing data. J Mol Diagn. 2014;16(5):504-518.
41. Getta BM, Devlin SM, Levine RL, et al. Multicolor Flow Cytometry and Multi-Gene Next Generation Sequencing are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia Following Allogeneic Transplant. Bio Blood Marrow Transplant. 2017;23(7):1064-1071
42. Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction proce- dures with censored survival data. Stat Med. 2011;30(10):1105-1117.
43. Westers TM, Cremers EM, Oelschlaegel U, et al. Immunophenotypic analysis of ery- throid dysplasia in myelodysplastic syn- dromes. A report from the IMDSFlow work- ing group. Haematologica. 2017;102(2):308-
Reizis B, Bunin A, Ghosh HS, Lewis KL,
Sisirak V. Plasmacytoid dendritic cells: recent
progress and open questions. Annu Rev
Immunol. 2011;29:163-183. 319.
Guilliams M, Ginhoux F, Jakubzick C, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014;14(8):571-578.
Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563-604. Derolf AR, Laane E, Bjorklund E, Saft L, Bjorkholm M, Porwit A. Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia. Scand J Immunol. 2014;80(6):424-431.
Rickmann M, Krauter J, Stamer K, et al. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann Hematol. 2011;90(9):1047-1058.
Rovati B, Mariucci S, Manzoni M, Bencardino K, Danova M. Flow cytometric detection of circulating dendritic cells in healthy subjects. Eur J Histochem. 2008;52(1):45-52.
Hsu AP, Johnson KD, Falcone EL, et al. GATA2 haploinsufficiency caused by muta- tions in a conserved intronic element leads to MonoMAC syndrome. Blood. 2013;121:3830-7, S1-7.
Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syn- drome. Blood. 2011;118(10):2653-2655. Naresh KN, Pavlu J. Plasmacytoid dendritic cell nodules in bone marrow biopsies of chronic myelomonocytic leukemia. Am J
44. Della Porta MG, Picone C, Pascutto C, et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica. 2012;97(8):1209-1217.
45. Ogata K, Della Porta MG, Malcovati L, et al. Diagnostic utility of flow cytometry in low- grade myelodysplastic syndromes: a prospective validation study. Haematologica. 2009;94(8):1066-1074.
46. Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15(8):471-485.
47. Allman D, Dalod M, Asselin-Paturel C, et al. Ikaros is required for plasmacytoid dendritic cell differentiation. Blood. 2006;108(13): 4025-4034.
48. Tassone L, Moratto D, Vermi W, et al. Defect of plasmacytoid dendritic cells in warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome patients. Blood. 2010;116(23):4870-4873.
49. Auletta JJ, Devine SM, Waller EK. Plasmacytoid dendritic cells in allogeneic hematopoietic cell transplantation: benefit or burden? Bone Marrow Transplant. 2016;51(3):333-343.
50. Elze MC, Ciocarlie O, Heinze A, et al. Dendritic cell reconstitution is associated with relapse-free survival and acute GVHD severity in children after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015;50(2):266-273.
51. Su RJ, Green R, Chen M. Enumeration of bone marrow plasmacytoid dendritic cells by multiparameter flow cytometry as a prognostic marker following allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis. 2018;69:107-112.
Tumorous proliferations of plasmacytoid dendritic cells and Langerhans cells associat- ed with acute myeloid leukaemia. Histopathology. 2012;61(5):974-983.
39. Vuckovic S, Fearnley DB, Gunningham S, Spearing RL, Patton WN, Hart DN. Dendritic cells in chronic myelomonocytic leukaemia. Br J Haematol. 1999;105(4):974-
haematologica | 2019; 104(7)
1387